Roche的实验性肥胖药物CT-388在第二阶段试验中造成了严重的体重减退和血糖的改善。 Roche's experimental obesity drug CT-388 caused significant weight loss and improved blood sugar in Phase 2 trials.

Roche报告说,其实验性肥胖药物CT-388(每周一次针对GLP-1和GIP受体的注射)的实验性肥胖药物CT-388的第二阶段试验取得了积极结果。 Roche has reported positive Phase 2 trial results for its experimental obesity drug CT-388, a weekly injectable targeting both GLP-1 and GIP receptors. 48周后,最高剂量(24毫克)导致平均22.5%的安慰剂调整后体重损失,其中87%至少损失10%,47.8%超过20%,26.1%超过30%。 After 48 weeks, the highest dose (24 mg) led to an average 22.5% placebo-adjusted weight loss, with 87% losing at least 10%, 47.8% over 20%, and 26.1% more than 30%. 在糖尿病前参与者中,73%达到了正常血糖水平,而安慰剂组为7.5%。 Among pre-diabetic participants, 73% achieved normal blood glucose levels, compared to 7.5% in the placebo group. 总的来说,该药物的开销良好,具有轻度至中度胃肠道副作用,停药率低。 The drug was generally well-tolerated, with mild to moderate gastrointestinal side effects and low discontinuation rates. Roche计划将CT-388推进到第三阶段试验,并继续扩大其代谢性疾病治疗组合。 Roche plans to advance CT-388 into Phase 3 trials and continues expanding its portfolio of metabolic disease treatments.